Sign in Register

Cancer Research

· 2 min read

Save

CDC conducts and supports studies to reduce cancer and eliminate health disparities.

Cancer Research

What to know

CDC’s Division of Cancer Prevention and Control conducts and supports studies to reduce cancer and eliminate health disparities.

Overview

Annual Report to the Nation on the Status of Cancer

Cancer death rates fell from 2019 to 2023, driven largely by progress against lung cancer.

Sept 21, 2026

CDC contributes data and scientific expertise on:

Cancer cases and treatment. Cancer prevention and risk behaviors. The quality and appropriate use of cancer screening.

The cost and cost-effectiveness of cancer control programs. Health and wellness after a cancer diagnosis. Efforts to advance health equity.

Resource

The U.S. Cancer Statistics Data Visualizations tool shows the official federal cancer statistics.

CDC's latest cancer research

Physical activity and perceptions of the community walking environment among cancer survivors, National Health Interview Survey, 2024 Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer Building computable guidelines and clinical decision support tools for cervical, breast and colorectal cancer screening and risk management: a CDC initiative update Pancreatic neuroendocrine and exocrine cancer incidence and stage at diagnosis before, during, and after the COVID-19 pandemic, United States, 2019–2022 Optimizing electronic reporting of pathology data to enhance efficiency in cancer registration to support cancer control planning

Resource

The Cancer Research Citation Search tool lists scientific articles by researchers in CDC's Division of Cancer Prevention and Control.

On This Page

Overview CDC's latest cancer research

Oct. 26, 2026 Sources and Page Info Print Share

Facebook LinkedIn Twitter Syndicate

Content Source

National Center for Chronic Disease Prevention and Health Promotion ; Division of Cancer Prevention and Control About This Page

Published: May 15, 2024

Updated: October 26, 2026 This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.

Reviewed: May 7, 2025 The information on this page was last reviewed by subject matter experts to ensure accuracy.

Content provided and maintained by the US Centers for Disease Control and Prevention (CDC). Please see our system usage guidelines and disclaimer .

Related articles

PubMed

Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.

Background: Dirozalkib is a highly selective anaplastic lymphoma kinase (ALK) inhibitor with intracranial antitumor activity against crizotinib-resistant mutations. This phase III trial evaluated dirozalkib versus crizotinib in patients with ALK inhibitor-naïve, ALK-positive, advanced non-small-cell lung cancer (NSCLC). Methods: In this multicenter, randomized, open-label DIAMOND-2 trial, adult patients with ALK inhibitor-naïve, ALK-positive, advanced NSCLC who either had received no prior syste...

PubMed

Geometry based gene-expression signatures detect cancer treatment responders in clinical trials.

Background Topological data analysis has had many developments with potential application to precision oncology. The goal of this study is to determine if using geometry-based methods of gene-expression signatures of tumors can be used to both create a definitive classification of responders and non-responders, and to predict patient treatment response using out-of-sample testing methodology. Methods Gene-expression signatures of tumors, constructed from geometrical attributes of data, were c...